Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been given an average rating of “Moderate Buy” by the six research firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.60.

IRWD has been the subject of several analyst reports. StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Finally, JMP Securities dropped their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares in the company, valued at $975,052.32. This represents a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 192,381 shares of company stock valued at $338,591 over the last quarter. Corporate insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. KBC Group NV increased its holdings in shares of Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,198 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Ironwood Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 3,209 shares in the last quarter. Creative Planning grew its position in Ironwood Pharmaceuticals by 12.7% during the 3rd quarter. Creative Planning now owns 42,151 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 4,749 shares in the last quarter. Quantinno Capital Management LP grew its position in Ironwood Pharmaceuticals by 40.0% during the 3rd quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 5,482 shares in the last quarter. Finally, Swiss National Bank grew its position in Ironwood Pharmaceuticals by 2.2% during the 4th quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company’s stock worth $1,252,000 after purchasing an additional 6,000 shares in the last quarter.

Ironwood Pharmaceuticals Trading Down 3.0 %

Shares of NASDAQ IRWD opened at $1.94 on Thursday. The stock has a 50 day simple moving average of $3.43 and a 200-day simple moving average of $4.00. The company has a market cap of $310.46 million, a PE ratio of -64.67 and a beta of 0.29. Ironwood Pharmaceuticals has a 12-month low of $1.59 and a 12-month high of $15.26.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.